138 related articles for article (PubMed ID: 9063692)
1. Pharmacological profile of YM087, a novel nonpeptide dual vasopressin V1A and V2 receptor antagonist, in dogs.
Yatsu T; Tomura Y; Tahara A; Wada K; Tsukada J; Uchida W; Tanaka A; Takenaka T
Eur J Pharmacol; 1997 Feb; 321(2):225-30. PubMed ID: 9063692
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological characterization of YM087, a potent, nonpeptide human vasopressin V1A and V2 receptor antagonist.
Tahara A; Saito M; Sugimoto T; Tomura Y; Wada K; Kusayama T; Tsukada J; Ishii N; Yatsu T; Uchida W; Tanaka A
Naunyn Schmiedebergs Arch Pharmacol; 1998 Jan; 357(1):63-9. PubMed ID: 9459574
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological profile of YM087, a novel potent nonpeptide vasopressin V1A and V2 receptor antagonist, in vitro and in vivo.
Tahara A; Tomura Y; Wada KI; Kusayama T; Tsukada J; Takanashi M; Yatsu T; Uchida W; Tanaka A
J Pharmacol Exp Ther; 1997 Jul; 282(1):301-8. PubMed ID: 9223568
[TBL] [Abstract][Full Text] [Related]
4. [Pharmacology of conivaptan hydrochloride (YM087), a novel vasopressin V1A/V2 receptor antagonist].
Yatsu T; Tomura Y; Tahara A; Wada K; Kusayama T; Tsukada J; Tanaka A; Iizumi Y; Honda K
Nihon Yakurigaku Zasshi; 1999 Oct; 114 Suppl 1():113P-117P. PubMed ID: 10629866
[TBL] [Abstract][Full Text] [Related]
5. Nonpeptide arginine vasopressin antagonists for both V1A and V2 receptors: synthesis and pharmacological properties of 4-(1,4,5,6-tetrahydroimidazo[4,5-d][1]benzoazepine-6-carbonyl)benzanili de derivatives and 4'-(5,6-dihydro-4H-thiazolo[5,4-d][1]benzoazepine-6-carbonyl)benzanilid e derivatives.
Matsuhisa A; Taniguchi N; Koshio H; Yatsu T; Tanaka A
Chem Pharm Bull (Tokyo); 2000 Jan; 48(1):21-31. PubMed ID: 10705470
[TBL] [Abstract][Full Text] [Related]
6. In vivo and in vitro characterisation of a nonpeptide vasopressin V(1A) and V(2) receptor antagonist (YM087) in the rat.
Risvanis J; Naitoh M; Johnston CI; Burrell LM
Eur J Pharmacol; 1999 Sep; 381(1):23-30. PubMed ID: 10528130
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological profile of orally administered YM087, a vasopressin antagonist, in conscious rats.
Tomura Y; Tahara A; Tsukada J; Yatsu T; Uchida W; Iizumi Y; Honda K
Clin Exp Pharmacol Physiol; 1999; 26(5-6):399-403. PubMed ID: 10386228
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic and pharmacodynamic effects of YM087, a combined V1/V2 vasopressin receptor antagonist in normal subjects.
Burnier M; Fricker AF; Hayoz D; Nussberger J; Brunner HR
Eur J Clin Pharmacol; 1999 Nov; 55(9):633-7. PubMed ID: 10638391
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular and renal effects of conivaptan hydrochloride (YM087), a vasopressin V1A and V2 receptor antagonist, in dogs with pacing-induced congestive heart failure.
Yatsu T; Tomura Y; Tahara A; Wada K; Kusayama T; Tsukada J; Tokioka T; Uchida W; Inagaki O; Iizumi Y; Tanaka A; Honda K
Eur J Pharmacol; 1999 Jul; 376(3):239-46. PubMed ID: 10448882
[TBL] [Abstract][Full Text] [Related]
10. Effect of YM087, a potent nonpeptide vasopressin antagonist, on vasopressin-induced protein synthesis in neonatal rat cardiomyocyte.
Tahara A; Tomura Y; Wada K; Kusayama T; Tsukada J; Ishii N; Yatsu T; Uchida W; Tanaka A
Cardiovasc Res; 1998 Apr; 38(1):198-205. PubMed ID: 9683922
[TBL] [Abstract][Full Text] [Related]
11. Effect of YM087, a potent nonpeptide vasopressin antagonist, on vasopressin-induced hyperplasia and hypertrophy of cultured vascular smooth-muscle cells.
Tahara A; Tomura Y; Wada K; Kusayama T; Tsukada J; Ishii N; Yatsu T; Uchida W; Tanaka A
J Cardiovasc Pharmacol; 1997 Dec; 30(6):759-66. PubMed ID: 9436815
[TBL] [Abstract][Full Text] [Related]
12. Binding characteristics of YM087, an AVP receptor antagonist, in rhesus monkey liver and kidney membranes.
Tahara A; Tomura Y; Wada K; Kusayama T; Tsukada J; Ishii N; Yatsu T; Uchida W; Tanaka A
Peptides; 1998; 19(4):691-6. PubMed ID: 9622024
[TBL] [Abstract][Full Text] [Related]
13. Nonpeptide vasopressin receptor antagonists: development of selective and orally active V1a, V2 and V1b receptor ligands.
Serradeil-Le Gal C; Wagnon J; Valette G; Garcia G; Pascal M; Maffrand JP; Le Fur G
Prog Brain Res; 2002; 139():197-210. PubMed ID: 12436936
[TBL] [Abstract][Full Text] [Related]
14. Effect of the vasopressin receptor antagonist conivaptan in rats with heart failure following myocardial infarction.
Wada K; Tahara A; Arai Y; Aoki M; Tomura Y; Tsukada J; Yatsu T
Eur J Pharmacol; 2002 Aug; 450(2):169-77. PubMed ID: 12206855
[TBL] [Abstract][Full Text] [Related]
15. Nonpeptide antagonists for vasopressin receptors. Pharmacology of SR 121463A, a new potent and highly selective V2 receptor antagonist.
Serradeil-Le Gal C
Adv Exp Med Biol; 1998; 449():427-38. PubMed ID: 10026834
[TBL] [Abstract][Full Text] [Related]
16. Nonpeptide arginine vasopressin antagonists for both V1A and V2 receptors: synthesis and pharmacological properties of 4'-[5-(substituted methylidene)-2,3,4,5-tetrahydro-1H-1-ben zoazepine-1-carbonyl]benzanilide and 4'-[5-(substituted methyl)-2,3-dihydro-1H-1-benzoazepine-1- carbonyl]benzanilide derivatives.
Matsuhisa A; Kikuchi K; Sakamoto K; Yatsu T; Tanaka A
Chem Pharm Bull (Tokyo); 1999 Mar; 47(3):329-39. PubMed ID: 10212383
[TBL] [Abstract][Full Text] [Related]
17. Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist.
Serradeil-Le Gal C; Lacour C; Valette G; Garcia G; Foulon L; Galindo G; Bankir L; Pouzet B; Guillon G; Barberis C; Chicot D; Jard S; Vilain P; Garcia C; Marty E; Raufaste D; Brossard G; Nisato D; Maffrand JP; Le Fur G
J Clin Invest; 1996 Dec; 98(12):2729-38. PubMed ID: 8981918
[TBL] [Abstract][Full Text] [Related]
18. Effect of conivaptan, a combined vasopressin V(1a) and V(2) receptor antagonist, on vasopressin-induced cardiac and haemodynamic changes in anaesthetised dogs.
Yatsu T; Kusayama T; Tomura Y; Arai Y; Aoki M; Tahara A; Wada K; Tsukada J
Pharmacol Res; 2002 Nov; 46(5):375-81. PubMed ID: 12419640
[TBL] [Abstract][Full Text] [Related]
19. Sodium excretion in response to vasopressin and selective vasopressin receptor antagonists.
Perucca J; Bichet DG; Bardoux P; Bouby N; Bankir L
J Am Soc Nephrol; 2008 Sep; 19(9):1721-31. PubMed ID: 18596120
[TBL] [Abstract][Full Text] [Related]
20. New topics in vasopressin receptors and approach to novel drugs: research and development of conivaptan hydrochloride (YM087), a drug for the treatment of hyponatremia.
Arai Y; Fujimori A; Sasamata M; Miyata K
J Pharmacol Sci; 2009 Jan; 109(1):53-9. PubMed ID: 19151543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
